| Hazard Information | Back Directory | [Uses]
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research[1]. | [in vivo]
KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model[1].
KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice[1]. | Animal Model: | SIRPA knock-in mouse model injected with Burkitt’s lymphoma cells[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; 10 mg/kg; every other day; 21 d | | Result: | Led to strong inhibition of tumor growth when combined with Rituximab. |
| [References]
[1] Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585. DOI:10.1073/pnas.1710877114 |
|
|